Osteocalcin promotes β-cell proliferation during development and adulthood through Gprc6a.
- Departments of 1 Genetics & Development and
- 2 Pathology & Cell Biology College of Physicians and Surgeons, Columbia University, New York, NY 10032
- Corresponding author: Patricia Ducy, E-mail:
Expanding β-cell mass through β-cell proliferation is considered a potential therapeutic approach to treat β-cell failure in diabetic patients. A necessary step toward achieving this goal is to identify signaling pathways that regulate β-cell proliferation in vivo. Here we show that osteocalcin, a bone-derived hormone, regulates β-cell replication in a CyclinD1-dependent manner by signaling through the Gprc6a receptor expressed in these cells. Accordingly, mice lacking Gprc6a in the β-cell lineage only are glucose intolerant due to an impaired ability to produce insulin. Remarkably, this regulation occurs both during the perinatal peak of β-cell proliferation and adulthood. Hence the loss of osteocalcin/Gprc6a signaling has a profound impact on β-cell mass accrual during late pancreas morphogenesis. This study extends the endocrine role of osteocalcin to the developmental period and establishes osteocalcin/Gprc6a signaling as a major regulator of β-cell endowment that can become a potential target for β-cell proliferative therapies.
- Received June 5, 2013.
- Accepted August 29, 2013.
- © 2013 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.